GSK’s Cervarix vaccine showed direct evidence of reducing cervical cancer occurrence rates. Credit: GSK / Flickr (Creative Commons).

China’s National Medical Products Administration (NMPA) has granted approval for GlaxoSmithKline’s (GSK) two-dose vaccine schedule, Cervarix, in girls between the age of nine to 14 years to prevent cervical cancer.

It is also indicated for preventing cervical intraepithelial neoplasia and adenocarcinoma in situ, linked to oncogenic human papillomavirus (HPV) types 16 and 18.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Cervarix is a recombinant, non-infectious, AS04-adjuvanted HPV bivalent (types 16, 18) vaccine.

With the latest approval, Cervarix became the first two-dose HPV vaccine imported for individuals of this age group in mainland China.

Apart from China, the two-dose vaccine regimen of Cervarix is approved in nearly 100 countries, including Asia, Africa, the European Union, and Latin America.

For girls and women aged 15 to 45 years, the three-dose vaccine regimen remains on the label in China.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company noted that the vaccine showed direct evidence of reducing cervical cancer occurrence rates. 

According to data from a register-based study in England, girls aged 12 to 13 years who received the vaccine doses had an 87% and 97% decline in cervical cancer and precancerous lesions such as cervical intraepithelial neoplasia (CIN) grade 3, respectively.

These findings signify a more substantial effect than anticipated based on the occurrence of the HPV 16/18 strains included in the vaccine.

The vaccine was found to be 93·2% effective against all CIN3+, regardless of HPV type in the lesion and including lesions with no HPV 16/18 DNA spotted, indicating a benefit broader than HPV 16/18.

Among all malignant tumours in the female reproductive system in China, cervical cancer has an increased mortality rate.

In April this year, the company entered an agreement to acquire Sierra Oncology for $1.9bn in cash.